Top-News

BioLineRX Aktie (ADR) News

Aktie
WKN:  A41038 ISIN:  US09071M3043 US-Symbol:  BLRX Branche:  Biotechnologie Land:  Israel
3,26 $
-0,06 $
-1,81%
2,8038 € 09.12.25
Depot/Watchlist
Marktkapitalisierung *
5,55 Mio. €
Streubesitz
94,51%
KGV
-70,83
Index-Zuordnung
-

BioLineRX Aktie (ADR) News

24.11.25 - PR Newswire
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
18.11.25 - PR Newswire
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 PR Newswire
17.11.25 - PR Newswire
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types PR Newswire
29.09.25 - PR Newswire
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-​in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other ...
14.08.25 - PR Newswire
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
07.08.25 - PR Newswire
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 PR Newswire
30.05.25 - PR Newswire
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-​Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting ...
27.05.25 - PR Newswire
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
20.05.25 - PR Newswire
BioLineRx to Report First Quarter 2025 Results on May 27, 2025
BioLineRx to Report First Quarter 2025 Results on May 27, 2025 PR Newswire
31.03.25 - PR Newswire
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
BioLineRx Reports 2024 Financial Results and Provides Corporate Update PR Newswire
24.03.25 - PR Newswire
BioLineRx to Report 2024 Annual Results on March 31, 2025
BioLineRx to Report 2024 Annual Results on March 31, 2025 PR Newswire
21.01.25 - PR Newswire
BioLineRx Issues Letter to Shareholders
BioLineRx Issues Letter to Shareholders PR Newswire
17.01.25 - PR Newswire
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares PR Newswire
06.01.25 - PR Newswire
BioLineRx Announces $10 Million Registered Direct Offering
BioLineRx Announces $10 Million Registered Direct Offering PR Newswire

Newssuche

Videos

newspaper
08.12.25 +5,61%
Technical Trading: Die besten 3 Tage
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »